Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1238

—

9c617ae5-8be7-5be0-8347-e987b5978d61

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • APICAL_JUNCTION+0.313
  • HEDGEHOG_SIGNALING+0.256
  • MYOGENESIS+0.256
  • CHOLESTEROL_HOMEOSTASIS+0.243
  • APICAL_SURFACE+0.241
  • PEROXISOME+0.190
  • FATTY_ACID_METABOLISM+0.164
  • XENOBIOTIC_METABOLISM+0.153
  • INTERFERON_ALPHA_RESPONSE+0.149
  • DNA_REPAIR+0.113

Top 10 suppressed

  • G2M_CHECKPOINT-0.471
  • E2F_TARGETS-0.422
  • TNFA_SIGNALING_VIA_NFKB-0.385
  • PROTEIN_SECRETION-0.348
  • MYC_TARGETS_V1-0.297
  • ANDROGEN_RESPONSE-0.274
  • MTORC1_SIGNALING-0.263
  • UNFOLDED_PROTEIN_RESPONSE-0.256
  • UV_RESPONSE_DN-0.230
  • ANGIOGENESIS-0.213

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1R56
bladder-landscape@3
——0.751
2SRR2932837
head-neck@1
——0.747
3MNG559
mng-umap@100
——0.747
4SRR6079989
head-neck@1
——0.745
562a2cbf8-51be-469b-978c-bdf386e0d651
colon-landscapes@1
——0.738
6MDT-AP-0759
medullo-epn-umap@date-based
MedMedulloblastoma0.721
7MDT-AP-0820
medullo-epn-umap@date-based
MedMedulloblastoma0.721
8MNG1263
mng-umap@100
——0.720
9MDT-AP-1197
medullo-epn-umap@date-based
MedMedulloblastoma0.716
10SRR1355635
brain-umap@2
GTEX—0.714

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
APICAL_JUNCTION0.313Inavolisib— uncovered
HEDGEHOG_SIGNALING0.256Inavolisib— uncovered
MYOGENESIS0.256Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.243Remibrutinib— uncovered
APICAL_SURFACE0.241Temsirolimus— uncovered
PEROXISOME0.190Idelalisib— uncovered
FATTY_ACID_METABOLISM0.164Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.153Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.149Inavolisib— uncovered
DNA_REPAIR0.113Idelalisib— uncovered
BILE_ACID_METABOLISM0.096Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.086Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.071Inavolisib— uncovered
P53_PATHWAY0.060Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.049Inavolisib— uncovered
ALLOGRAFT_REJECTION0.038Idelalisib— uncovered
KRAS_SIGNALING_DN0.023Remibrutinib— uncovered
ADIPOGENESIS0.022Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.014Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.002Idelalisib— uncovered